# GI Innovation, Inc.: Phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC) (107 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | GI Innovation, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201) |
| NCT ID | NCT07871435 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Metastatic Castration-resistant Prostate Cancer (mCRPC) |
| Intervention types | drug |
| Target enrollment | 107 |
| Site countries | United States, South Korea |
| Posted | 2026-10-13 |
| Planned start | 2026-10-12 |
| Event | Newly registered study |
| Event date | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.
- 107 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07871435). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.